1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMeticraneCat. No.: HY-B0908CAS No.: 1084-65-7分式: CHNOS分量: 275.34作靶點: Sodium Channel; Chloride Channel作通路: Membrane Transporter/Ion Channel儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 50

2、mg/mL (181.59 mM)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (9.08 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (9.08 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 m

3、g/mL (9.08 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Meticrane種利尿劑。Meticrane 抑制遠曲管中鈉離和氯離的重 吸收。Meticrane 可于治療原發性壓。IC50 & Target Sodium and chloride ion 1體內研究 Meticrane, a thiazide diuretic is highly ranked in the connectivity map (cMap) analysis, and it does not haveany known anti-cancer or immune-st

4、imulating effect. Co-treatment with Meticrane significantly enhancestreatment efficacy of CTLA-4 blockade 2.PROTOCOLAnimal Mice 2Administration 2 Meticrane is dissolved in DMSO to a concentration of 160mg/mL. BALB/c (H-2d) mice receive daily i.p.injections at a dose of 400mg/kg bodyweight for 10 day

5、s post anti-CTLA4 treatment. The thiazide diureticMeticrane is used at doses of 150-300mg once daily; the reported LD50 for mice is 10g/kg after i.p.administration. 3 groups of standard BALB/c mice are treated consecutively (n=3/group) with increasingdoses of Meticrane i.p. (100mg/kg; 200mg/kg and 4

6、00mg/kg) for 10 days and monitored weight and generalwellbeing.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Rumiko TANAKA, et al. Crystal Structure of Meticrane. ANALYTICAL SCIENCES 2007, VOL. 23.2. Lesterhuis WJ, et al. Network analysis of immunotherapy-induced regressing tumours identifies novel synergisticdrug combinations. SciRep. 2015 Jul 21;5:12298.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.T